Continued access to avutometinib plus defactinib for recurrent low-grade serous ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial lets people who are already doing well on a study treatment keep receiving it. It tests whether continuing the combination of avutometinib and defactinib remains safe and helpful for recurrent low-grade serous ovarian cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking avutometinib and defactinib in the RAMP-201 study and have not stopped permanently.
- Your doctor agrees that you are benefiting from the treatment (e.g., tumor shrinkage or stable disease).
- If you can become pregnant, you must agree to use highly effective birth control during the study and for 30 days after the last dose.
- You must not have had disease progression or stopped treatment for any reason during the RAMP-201 study.
- You must not have started any new cancer treatment since joining the RAMP-201 study.
- You must not have certain eye conditions or take medications that could interact with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether regorafenib (a targeted pill) plus fulvestrant (an injection that lowers estrogen signaling) can slow down recurrent low-grade serous ovarian cancer. It may help people whose cancer has returned after prior treatments.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new experimental drug (JPI-547) combined with bevacizumab (a targeted therapy) as maintenance treatment for recurrent ovarian cancer after initial response to platinum-based chemo. The goal is to see if this combination can keep the cancer from growing longer than standard care.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.